Meeting
2016 ASCO Annual Meeting
Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).
Authors
David A. Reardon
Dana-Farber Cancer Institute/ Harvard Cancer Center, Boston, MA
David A. Reardon , Thomas Joseph Kaley , Jorg Dietrich , Michael Lim , Gavin P Dunn , Hui Kong Gan , Timothy Francis Cloughesy , Jennifer Leigh Clarke , Andrew J. Park , Mary J. Macri , Aileen Ryan , Toni Ricciardi , Vijay Reddy , Ralph Rudolph Venhaus
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT02336165
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS2080)
DOI
10.1200/JCO.2016.34.15_suppl.TPS2080
Abstract #
TPS2080
Poster Bd #
266a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).
First Author: David A. Reardon
Poster
2019 ASCO Annual Meeting
Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).
First Author: David A. Reardon
Poster
2023 ASCO Annual Meeting
A phase II study to evaluate the efficacy and safety of combination therapy of durvalumab (MEDI4736) and amrubicin in patients with recurrent small cell lung cancer (SCLC): Aphrodite trial, in progress.
First Author: Yuka Kato
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu